List All Leukemia Trials

Leukemia

 

CPX-351 Versus 7+3 for Older Patients (2651)
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Closed;   Study ID: NCT01696084

GS-1101 (CAL-101) for Previously Treated Chronic Lymphocytic Leukemia (FH 2693)
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Closed;   Study ID: NCT01659021

Adoptive Immunotherapy for Relapsed AML, MDS, or CML (FH 2498)
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML

Investigator: Dan Egan, MD;   Conditions: Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Leukemia;    Status: Recruiting;   Study ID: NCT01640301

Cord Blood Cell Infusion Post Chemotherapy for AML (2584)
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Induction Chemotherapy (FLAG) in Patients with Relapsed/Refractory AML

Investigator: Colleen Delaney, MD, MSc;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia;    Status: Recruiting;   Study ID: NCT01701323

Decitabine + Mitoxantrone Hydrochloride, Etoposide, and Cytarabine for AML or MDS (2652)
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01729845

Radioimmunotherapy + SCT for Advanced AML, ALL, or MDS
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate

Investigator: John M. Pagel, MD;   Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT00988715

Decitabine Followed by Idarubicin and Cytarabine for AML or MDS
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML

Investigator: Derek L. Stirewalt, MD;   Conditions: Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01607645

Umbilical Cord Blood Transplant w/wo Ex-Vivo Expanded Cord Blood Progenitor Cells
Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-the-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies

Investigator: Colleen Delaney, MD;   Conditions: Leukemia;    Status: Pending;   Study ID: NCT01690520

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride for Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) (2734)
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT02044796

AMG 232 for Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02016729

Outpatient Induction Chemotherapy for Newly Diagnosed AML or MDS (7910)
Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Investigator: Pamela S. Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01807091

Liposomal Cytarabine-Daunorubicin CPX-351 for Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (2642)
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

Investigator: Roland B. Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01804101

Decitabine and Cytarabine for Newly Diagnosed AML, High Risk MDS or MPN (9019)
Decitabine plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MDS);    Status: Recruiting;   Study ID: NCT02121418

Standard of Care w/wo Midostaurin to Prevent Relapse Post Transplant (9037)
A Phase II, Randomized, Comparative Trial of Standard of Care, with or without Midostaurin to Prevent Relapse following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia

Investigator: Bart Scott, MD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01883362

SGN-CD33A for Newly Diagnosed Acute Myeloid Leukemia (9233)
A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML)

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02326584

Telemonitoring Outpatient Management Post Intensive Chemotherapy (9105)
Integrating a Telemonitoring Device into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study

Investigator: Roland Walter, MD;   Conditions: Leukemia, Myelodysplastic Syndromes , Myeloproliferative Syndromes;    Status: Recruiting;   Study ID: NCT02226497

ABT-199 + Low-Dose Cytarabine Acute Myelogenous Leukemia (9237)
A Phase 1/2 Study of ABT-199 in Combination with Low-Dose Cytarabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are >= 65 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02287233

ABT-199 + Decitabine or Azacitidine for Acute Myelogenous Leukemia (20141655)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy

Investigator: Pamela Becker, MD, PhD;   Conditions: Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia; Leukemia, Myeloid;    Status: Recruiting;   Study ID: NCT02203773

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (9226)
Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Leukemia;    Status: Recruiting;   Study ID: NCT02551718

SL-401 Acute Myeloid Leukemia in First Complete Remission
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

Investigator: Roland Walter, MD;   Conditions: Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia; Leukemia, Myeloid; Neoplasms;    Status: Recruiting;   Study ID: NCT02270463

Ibrutinib or Idelalisib for Relapsed B-cell Malignancies Following Stem Cell Transplantation (2561.00)
A Phase II, Non-Randomized, Single Institution, Clinical Trial of Signal Transduction Inhibitors, Ibrutinib or Idelalisib, To Treat Patients with Persistent or relapsed B-cell Malignancies Following Allogeneic Hematopoietic Cell Transplantation.

Investigator: Mohamed Sorror, MD, MSc;   Conditions: Leukemia, Chronic Lymphocytic Leukemia; Hematologic Malignancies; Non-Hodgkin's Lymphoma;    Status: Recruiting;   Study ID: NCT02662296

ADCT-301 for CD25-positive Acute Myeloid Leukemia (9513)
A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia

Investigator: Roland Walter, MD;   Conditions: Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia;    Status: Recruiting;   Study ID: NCT02588092

Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia

Investigator: Rebecca Gardner, MD;   Conditions: CD19+ Leukemia;    Status: Recruiting;   Study ID: NCT02028455

After Stopping Tyrosine Kinase Inhibitors for CML
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Investigator: Vivian Oehler, MD;   Conditions: Chronic Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02269267